Opko Health, Inc. Acquires Worldwide Ophthalmic Rights to Teva Pharmaceutical Industries Limited's Budesonide for Inflammatory and Allergic Ocular Conditions

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (AMEX:OPK) today announced that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd. (TEVA) to Teva’s proprietary formulation of budesonide for the treatment of various inflammatory and allergic conditions of the eye. Teva’s proprietary budesonide product is currently marketed in Italy under the tradename XAVIN for the treatment of asthma.

Back to news